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Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, United StatesSummary and the potential adverse impact that DILI may have on patientStudies of boceprevir and telaprevir based antiviral therapy in
liver transplant (LT) recipients with hepatitis C genotype 1 infec-
tion have demonstrated dramatic increases in tacrolimus, cyclo-
sporine, and mTOR inhibitor exposure. In addition to empiric
dose reductions, daily monitoring of immunosuppressant blood
levels is required when initiating as well as discontinuing the
protease inhibitors to maximize patient safety. Although
improved suppression of HCV replication is anticipated, 20 to
40% of treated subjects have required early treatment discontin-
uation due to various adverse events including anemia (100%),
infection (30%), nephrotoxicity (20%) and rejection (5 to 10%).
Simeprevir and faldaprevir will likely have improved efﬁcacy
and safety proﬁles but potential drug interactions with other
OATP1B1 substrates and unconjugated hyperbilirubinemia are
expected. In contrast, sofosbuvir and daclatasvir based antiviral
therapy are not expected to lead to clinically signiﬁcant drug-
drug interactions in LT recipients but conﬁrmatory studies are
needed. Liver transplant recipients may also be at increased risk
of developing drug induced liver injury (DILI). Establishing a diag-
nosis of DILI in the transplant setting is very difﬁcult with the
variable latency, laboratory features and histopathological mani-
festations of hepatotoxicity associated with a given drug, the
need to exclude competing causes of allograft injury, and the lack
of an objective and veriﬁable conﬁrmatory test. Nonetheless, a
heightened awareness of the possibility of DILI is warranted in
light of the large number of medications used in LT recipientsJournal of Hepatology 20
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The calcineurin inhibitors (CNI), tacrolimus and cyclosporine, as
well as the mammalian target of rapamycin inhibitors (mTORi),
sirolimus and everolimus, are the backbone of modern immuno-
suppression in solid organ transplantation. Both of these drug
classes are substrates of cytochrome P450 (CYP) isoenzymes
3A4/5 and the drug-transporter, P-glycoprotein (P-gp). These
metabolic pathways are also primarily involved in the elimina-
tion of 40 to 60% of all marketed drugs and in vivo expression
of both CYP3A4/5 and P-gp vary substantially between individuals
[1–6]. As a result, administration of a drug that is a CYP3A or P-gp
substrate/inhibitor to a liver transplant (LT) recipient can lead to
dangerously high immunosuppressant blood levels, while intake
of CYP3A inducers can predispose to subtherapeutic dosing and
rejection [4,5]. Therefore, transplant practitioners must be
knowledgeable of the pharmacokinetic and potential drug-drug
interaction (DDI) proﬁles of many drugs.
The azole antifungals and non-dihydropyridine calcium
channel blockers are commonly prescribed drugs that can
increase the blood levels of CNI’s and mTORi’s. For example, a
200 mg dose of ﬂuconazole will increase the area under the curve
(AUC) of cyclosporine by 1.8-fold and increase the tacrolimus
trough concentration by 5-fold in transplant recipients [7].
Similarly, intake of CYP3A inducers such as carbamazepine, St.
John’s wort, and rifampin can lead to increased metabolism and
reduced bioavailability of both CNI’s and mTORi’s [8]. Boceprevir
(BOC) and telaprevir (TPV) are NS3 protease inhibitors approved
for use in combination with peginterferon (PegIFN) and ribavirin
(RBV) for patients with chronic hepatitis C virus (HCV) genotype
1 infection. Both BOC and TPV are potent substrates and inhibi-
tors of CYP3A and have demonstrated signiﬁcant interactions
with the CNI’s and mTORi’s in healthy volunteers as well as LT
recipients. In this article, potential drug-interactions of BOC and
TPV with immunosuppressants and other commonly used
medications will be reviewed. In addition, preliminary safety
and efﬁcacy data of these drugs as well as other newer direct
acting antiviral agents (DAA’s) in LT recipients will be provided.14 vol. 60 j 872–884
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Lastly, a review of the incidence, presentation, and outcomes of
drug induced liver injury (DILI) in LT recipients will be provided.The ﬁrst generation HCV protease inhibitors: Boceprevir and
telaprevir
Hepatitis C remains the leading indication for LT in most western
countries and is associated with nearly universal recurrence of
HCV replication and damage in the allograft [9,10]. The rate of
liver disease and ﬁbrosis progression in LT recipients is greatly
accelerated compared to non-transplant patients with 20%
developing cirrhosis within 5 years of transplant and 1 to 5%
developing rapidly progressive and frequently fatal ﬁbrosing
cholestatic hepatitis (FCH) [11]. As a result, PegIFN and RBV com-
bination therapy is frequently used in selected LT recipients
[12,13]. However, many LT recipients have contraindications to
PegIFN therapy and rates of sustained virologic response (SVR)
are substantially lower in LT recipients compared to non-trans-
plant patients (e.g., 20% to 30% vs. 45% in HCV genotype 1)
[12,13]. The lower observed SVR rates are attributed to the use
of immunosuppressant agents that enhance viral replication
and the need for frequent antiviral dose reductions (50 to 70%)
and early antiviral treatment discontinuation (20 to 40%)
[12,14]. Furthermore, there are increasing reports of immune-
mediated allograft dysfunction due to PegIFN that may not only
require early discontinuation of treatment, but also lead to pre-
mature graft failure and/or death [15–17]. However, since LT
recipients who achieve SVR have a signiﬁcantly improved sur-
vival compared to non-responders, there is an urgent unmet
medical need to develop safer and more effective therapies for
LT recipients [18,19].
BOC and TPV in combination with PegIFN and RBV signiﬁ-
cantly improve SVR rates in both treatment naïve and previously
treated patients with HCV genotype 1 infection compared to Peg-
IFN and RBV alone [20,21]. In addition, only 6 months of response
guided therapy is required in 50 to 60% of non-cirrhotic patients
[20,22–25]. However, use of these agents is also associated with
various adverse events including rash (50%), anorectal symptoms
(30%), and anemia (50%) with TPV, and dysgeusia (30%) and ane-
mia (50%) with BOC treatment [26,27]. Although both of these
agents carry warnings regarding the potential for DDI’s with CNI’s
and mTORi’s, the anticipated improvement in antiviral efﬁcacy
has generated a great deal of interest in using them in the trans-
plant setting [28].Drug-drug interactions with boceprevir and telaprevir
Boceprevir and TPV are extensively metabolized in the liver and
both drugs are substrates and inhibitors of CYP3A. Telaprevir is
also a potent substrate and inhibitor of P-gp. Since elimination
of BOC is dependent on multiple routes of metabolism, BOC is
anticipated to be associated with less severe DDI’s with CYP3A
substrates compared to TPV [28,29].
Co-administration of BOC and TPV with drugs metabolized by
CYP3A can lead to increased pharmacodynamic effects of those
concomitant drugs, due to reduced metabolism and increased
bioavailability in the non-transplant setting [30–34]. For exam-
ple, the area-under the curve (AUC) and maximum concentration
(Cmax) of a 20 mg dose of atorvastatin increased 7.9 and 10.6-fold,Journal of Hepatology 201respectively, with TPV co-administration, while BOC increased
the AUC and Cmax of a single 40 mg dose of atorvastatin by 2.3-
and 2.7-fold, respectively [33,35]. Therefore, atorvastatin should
not be co-administered with TPV and the lowest possible dose
of atorvastatin should be used in patients receiving BOC. Alterna-
tively, pravastatin which is a weak inhibitor of CYP3A may be a
suitable alternative [33]. Similarly, the dose of intravenous
midazolam should be reduced by at least 50% in patients receiv-
ing BOC or TPV [30,36]. Digoxin levels are increased 18% when
co-administered with BOC and increased 85% when co-adminis-
tered with TPV [30,36]. These latter data suggest that TPV is a
moderate inhibitor of P-gp while BOC appears to be a mild P-gp
inhibitor [31].
Use of BOC and TPV may also alter the bioavailability and
pharmacodynamic effect of some concomitantly administered
medications. For example, both BOC and TPV lower the AUC of
ethinyl estradiol by approximately 25%, which may result in
the loss of contraceptive efﬁcacy [30,37]. In addition, BOC and
TPV have differing effects on the bioavailability of the progestin
component of oral contraceptives [30]. Since ribavirin is highly
teratogenic, two alternative forms of contraception, such as an
intrauterine device and barrier methods, are recommended dur-
ing and after treatment with BOC or TPV based therapy
[26,27,30].
Concomitant administration of CYP3A inhibitors and inducers
may also alter the pharmacokinetics and pharmacodynamics of
BOC and TPV during antiviral therapy (Supplementary Table 1).
For example, administration of carbamazepine, a CYP3A inducer,
may lower serum BOC and TPV levels and increase the risk of
drug resistant variants developing in HCV patients. In contrast,
drugs that are CYP3A inhibitors, such as the macrolide antibiotics,
may lead to increased BOC or TPV exposure and increase the
severity and frequency of adverse events [26,27,34]. Therefore,
reviewing all concomitant medications prior to BOC or TPV based
therapy is required. If (a) concomitant medication(s) metabolized
by CYP3A or P-gp is required, the lowest effective dose should be
used or an agent that is not heavily dependent on CYP3A could be
considered (Table 1).Effects of telaprevir and boceprevir on immunosuppressant
drug levels
One of the greatest challenges of using BOC and TPV in the LT
population is the dramatic effect that BOC and TPV have on CNI
and mTORi blood levels [28,30,38]. In one study of healthy volun-
teers, the AUC of cyclosporine increased 4.6 and 2.7-fold when
co-administered with TPV and BOC, respectively (Supplementary
Table 2). In addition, the AUC of tacrolimus increased 70.3- and
17.1-fold when co-administered with TPV and BOC in healthy
individuals, respectively [39,40]. Lastly, a study of BOC with sin-
gle dose sirolimus in healthy volunteers showed a signiﬁcant
increase in the AUC and Cmax of sirolimus by 8.1 and 4.8-fold,
respectively [41]. Currently, use of BOC and TPV in subjects
receiving CNI’s and mTORi is considered a relative to absolute
contraindication until additional safety data are obtained [26,27].
Despite the aforementioned concerns, several studies have
begun to explore the use of BOC and TPV in combination with
PegIFN and RBV in carefully monitored LT recipients (Table 2).
A substantial reduction in the clearance of tacrolimus (80%),
cyclosporine (50%), and everolimus (53%) was reported in LT4 vol. 60 j 872–884 873
Table 1. Selected drugs that should be used with caution in subjects receiving boceprevir or telaprevir based antiviral treatment.
Drug class Effect on concomitant drug bioavailability
(Clinical impact)
Alternative agent(s) and management
Macrolide antibiotics
Clarithromycin
Erythromycin
Telithromycin^
Increased 
(QT prolongation; torsade de pointes)
Amoxicillin
Cefazolin
Clindamycin
Trimethoprim/sulfamethoxazole
Metronidazole
Levofloxacin
Ciprofloxacin
Antidepressants
Escitalopram* Decreased
(Decreased efficacy)
Citalopram
Sertraline
Venlafaxine
Duloxetine
Trazodone
Despiramine**
Increased
(Dizziness, hypotension, nausea)
As above
Use lower dose of trazodone
Anti-fungals
Itraconazole
Ketoconazole
Posaconazole
Voriconazole***
Increased
(QT prolongation, diarrhea, vomiting)
Ketoconazole dose not to exceed 200 mg/day
Fluconazole
Micafungin
Caspofungin
Calcium channel blockers
Amlodipine
Diltiazem
Nicardipine
Nifedipine
Verapamil
Increased
(Hypotension, bradycardia)
Consider amlodipine dose reduction
Metoprolol, atenolol
Hydrochlorothiazide
Lisinopril, benazepril
Losartan, valsartan
Clonidine
Immunosuppressants
Cyclosporine
Everolimus
Sirolimus
Tacrolimus
Increased
(Nephrotoxicity, hypertension, neurotoxicity) levels
Significant dose reductions and close monitoring of drug
Prednisone
Methylprednisolone
Increased 
(Hyperglycemia, osteoporosis, insomnia)
Risk vs. benefit
Antiarrhythmic
Amiodarone
Propafenone
Lidocaine
Quinidine
Increased
(Proarrhythmic)
Digoxin Increased
(Digoxin toxicity)
Use lowest dose and monitor digoxin levels
Use lowest effective dose
⁄Only reported with TPV.
⁄⁄Only reported with BOC.
⁄⁄⁄Not recommended to be used with TPV. TPV co-administration may increase or decrease voriconazole.
Adapted from boceprevir and telaprevir package insert [26,27].
Please consult package inserts for complete list of known drug interactions and recommended management.
^Telithromycin has a black-boxed warning regarding hepatotoxicity and should be avoided in LT recipients.
Frontiers in Liver Transplantationrecipients receiving BOC with PegIFN and RBV [42]. In addition, a
signiﬁcant reduction in the clearance of both cyclosporine and
tacrolimus in LT recipients receiving TPV and PegIFN and RBV
therapy was reported [43]. The median weekly dose of tacrolimus
and cyclosporine during TPV treatment was 4% and 14% of the
pretreatment dose, respectively [43]. Similarly, the AUC of siroli-
mus increased 26-fold and the mean terminal half-life increased
1.5-fold in 5 patients receiving TPV and PegIFN and RBV [44].
During the 12 weeks of TPV therapy, patients required only 3 to
33% (mean 11%) of the pretreatment sirolimus dose with doses
ranging from 0.5 to 1 mg every 5 to 22 days [44].
Prednisone and methylprednisolone are also substrates of
CYP3A and one study demonstrated a 37% increase in874 Journal of Hepatology 201prednisolone AUC when co-administered with BOC [45].
Although the increase in prednisolone concentration is unlikely
to be clinically signiﬁcant, additional studies in LT recipients
are needed [26,27,45].Boceprevir and telaprevir based antiviral therapy in LT
recipients
There are several ongoing studies of BOC and TPV in combination
with PegIFN and RBV in LT recipients with recurrent HCV geno-
type 1 (Table 2) [46–52]. In one study, 35 patients treated with
TPV, PegIFN, and RBV were followed for a mean of 32 weeks4 vol. 60 j 872–884
Table 2. Ongoing studies of boceprevir and telaprevir with PegIFN and RBV in LT recipients with HCV genotype 1.
Study, [Ref.], 
n
Antiviral regimen Immuno-
suppressant
% HCV RNA 
undetectable
Immunosuppressant 
dose adjustments
% Adverse events
Coily, [47],
n = 37
BOC
4 wk PegIFN + RBV then BOC + PegIFN/
RBV
N = 18
Mean Rx = 41 wk
BOC
CSA = 12
TAC = 6
BOC
56% Wk 8
89% Wk 16
72% Wk 48
11% 
early viral 
breakthrough
BOC
CSA 36% of original dose
TAC 22% of original dose 
BOC
100% Anemia
61% Neutropenia
50% Thrombocytopenia
5% Rash
5% Nephrotoxicity
26% Infections
33% Hospitalization
11% Death
TPV
4 wk PegIFN + RBV; TPV + PegIFN + RBV 
x 12 wk then PegIFN + RBV
N = 19
Mean Rx = 41 wk
TPV
CSA = 10
TAC = 9
TPV
47% Wk 8
58% Wk 16
21% Wk 48
21% 
early viral 
breakthrough
TPV
CSA 54% of original dose
TAC 5% of original dose
All patients hospitalized for CNI 
dose adjustments
TPV
84% Anemia
21% Neutropenia
15% Thrombocytopenia
5% Rash
21% Nephrotoxicity
27% Infections
31% Hospitalization
5% Death
Pungpapong, 
[46], 
n = 60
BOC
4 wk PegIFN + RBV then BOC + PegIFN/
RBV (n = 25)
Mean Rx = 39 wk
BOC
CSA = 23
TAC = 2
BOC
24% Wk 8 
40% Wk 12
12% 
early viral 
breakthrough
BOC
CSA 33-100% (mean 56%) of 
original dosed every 12 hr
TAC 86% reduction of original 
dose dosed twice wkly to every 
48  hr
BOC
100% Anemia 
76% Leukopenia 
36% SCr increased >0.5 mg/dl 
32% Rash
4 % Infections
4% Acute rejection 
4% Death 
TPV
TPV + PegIFN/RBV x 12 wk then PegIFN/
RBV (n = 35) 
Mean Rx = 32 wk
TPV
CSA = 33
SRL = 1
TAC = 1
TPV
17% Wk 4 
80% Wk 12
8% early 
viral 
breakthrough
 
TPV
CSA 50-100% (mean 70%) of 
original dose every 12 hr
SRL = 0.5 mg every 4 days
TAC = 0.5 mg every 7 days
TPV
88% Anemia 
77% Leukopenia 
11% SCr increased >0.5 mg/dl
31% Rash
6% Infections
6% Acute rejection
3% Death
Werner, [49], 
n = 9
TPV
TPV + PegIFN/RBV x 12 wk then PegIFN/
RBV
Mean Rx =  12 wk 
TPV
CSA = 4
TAC = 4
SRL = 1
TPV
44% Wk 4 
88% Wk 12
TPV-Fold dose reduction
TAC = 22 (96%)
SRL = 7 (86%)
CSA = 2.5 (60%)
Immunosuppressant interval
TAC - single dose per wk
SIRL - single dose per wk
CSA - single dose daily
TPV
66% Anemia 
66% Leukopenia 
44% Thrombocytopenia 
33% Rash 
44% Hospitalized infection 
11% Renal failure 
Brown, [48], 
n = 46
TPV
TPV + PegIFN/RBV x 12 wk then PegIFN/
RBV
Mean Rx = 16 wk
TPV
TAC = 39
CSA = 7
TPV
53% Wk 4 
60% Wk 12 
TPV
CSA reduced 4X
TAC reduced 10X
Med time to 1st TAC dose = 74 hr
Median TAC dose = 0.5 mg every 
7 days
Med time to 1st CSA dose 25 hr
Med CSA dose = 25 every 24 hr
TPV
48% Anemia 
35% Rash (mild) 
41% Anorectal symptoms 
22% Pruritus 
11% Renal failure 
 4% Supratherapeutic CNI 
level (discontinued TPV) 
O’Leary, 
[44], 
n = 120**
TPV/BOC
TPV (n = 107) or BOC (n = 13) + PegIFN ± 
PegIFN/RBV lead-in (n = 116)
Median Rx = 148 days
TPV/BOC
TAC = 35
CSA = 73
TPV/BOC
63% Wk 4 
78% Wk 12
72% Wk 24
7% viral 
breakthrough
TPV/BOC
Median daily dose prior and after 
initiation of TPV or BOC
CSA = 200 mg/ 50 mg
TAC = 1.0 mg/ 0.19 mg
TPV/BOC
79% Anemia
45% Blood transfusion 
43% GCSF 
20% Hospitalization 
33% Scr increased >0.5 mg/dl 
6% Acute rejection 
2% Death 
BOC, boceprevir; CSA, cyclosporine; EVRL, everolimus; IS, immunosuppression; MMF, mycophenolate mofetil; PegIFN, peginterferon; RBV, ribavirin; Rx, treatment duration;
Scr, serum creatinine; SIRL, sirolimus; TAC, tacrolimus; TPV, telaprevir.
⁄One patient received prolonged-release (once daily) tacrolimus.
⁄⁄6 liver-kidney transplant recipients.
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and 25 BOC treated patients were followed for a mean of
39 weeks [46]. Prior to initiation of treatment, 92% of the patients
were converted to cyclosporine. Thus far, 14 (67%) TPV and 10
(45%) BOC treated patients had undetectable HCV RNA at week
24 and 3 (5%) had developed viral breakthrough. Despite restrict-
ing the initial ribavirin dose to 800 mg/day, anemia was encoun-
tered in 100% of the patients and 50% required a blood
transfusion. In addition, biopsy-proven rejection due to subther-
apeutic cyclosporine levels occurred in two patients during TPV
therapy and another patient following discontinuation of BOC.
Of the two patients that died, one with FCH developed sepsis
after treatment of rejection and the other patient had decompen-
sation prior to starting antiviral therapy.
The preliminary results of a multicenter French study of 37 LT
recipients treated with either BOC or TPV were recently pub-
lished [47]. Sixteen percent of these patients had FCH and 51%
had received prior antiviral therapy post LT. A 4-week lead-in
of PegIFN and RBV was given to 84% of patients and all of the
patients were hospitalized when BOC or TPV was started to mon-
itor CNI levels. Quite remarkably, 89% of the BOC and 58% of the
TPV treated patients had an undetectable HCV RNA at week 16.
However, early discontinuation of therapy was required in 58%
of the TPV treated patients due to severe infections or a lack of
response, while only 28% of the BOC treated patients required
early discontinuation of therapy. Although follow-up is ongoing,
71% of the BOC treated patients and 20% of the TPV treated
patients with a week-48 response have remained HCV RNA neg-
ative at post-treatment week 12. Anemia was encountered in
100% of the patients and 35% required a blood transfusion. Only
one episode of mild rejection was reported, but 8% died of
liver-related complications.
The preliminary results of the ongoing REFRESH study demon-
strate more promising outcomes with TPV use in 46 LT recipients
with 53% and 60% of patients achieving undetectable HCV RNA at
weeks 4 and 12, respectively [48]. The most frequent adverse
events include anemia (48%) and rash (35%) but follow-up is
ongoing.
Overall, these preliminary data suggest that the addition of
TPV or BOC to PegIFN and RBV can lead to increased rates of
HCV RNA suppression in LT recipients compared to historical con-
trols. However, the dose of CNI needs to be markedly reduced
during BOC and TPV therapy with highly variable dosing intervals
necessitating the need for frequent therapeutic drug monitoring.
In addition, a rapid increase in the CNI dosing and frequency is
required within 1 to 2 days of discontinuing BOC or TPV to min-
imize the risk of under immunosuppression and rejection [53].Adverse effects of boceprevir and telaprevir in LT recipients
Anemia has been a universal and potentially severe adverse event
with BOC and TPV therapy in LT recipients [46–54]. This is, in
part, due to the impaired clearance of RBV in LT recipients with
renal insufﬁciency as well as the bone marrow suppressive
effects of PegIFN, BOC, and TPV [54,55]. Despite a lower starting
dose of RBV, aggressive RBV dose reductions have been needed
and erythropoietin stimulating agents (ESA) have been used in
60 to 90% of treated patients [46–52]. Skin rashes have also been
frequently noted but they have not been severe [46–51]. Mild to
moderate renal insufﬁciency has also been reported during triple
antiviral therapy, which may, in part, be due to drug-drug876 Journal of Hepatology 201interactions with the CNI’s [44–49,52,56]. However, recent stud-
ies in non-transplant patients have demonstrated signiﬁcant but
reversible reductions in renal function with TPV and BOC therapy
attributed to renal tubular transporter effects [56,57]. Due to
these safety concerns, frequent therapeutic drug monitoring
and assessment of renal function is recommended in LT
recipients receiving these agents. Bacterial infections resulting
in hospitalization or even death have also been reported in up
to 33% of LT recipients further highlighting the need for frequent
and vigilant clinical assessment of all treated patients
[46,47,59,50].CNI and mTORi dosing during and after telaprevir and
boceprevir therapy
Empiric adjustments of the CNI and mTORi dose and interval
must be made at the time of initiation of BOC or TPV to minimize
the risk of toxicity. Currently, prospective studies to provide safe
and accurate estimates of the extent of CNI dose reduction are
ongoing [43]. However, since the severity of the CYP3A interac-
tion is less with cyclosporine compared to tacrolimus, many cen-
ters have opted for conversion to cyclosporine prior to initiating
BOC or TPV therapy in LT recipients. Regardless of the CNI or
mTORi used, immunosuppressant blood levels should be stable
and within therapeutic range for at least 1 month prior to starting
antiviral therapy (Supplementary Table 3). In addition, there is
limited data in LT recipients with a history of severe rejection
requiring antiviral therapy. Most studies have withheld CNI dos-
ing after the initiation of TPV and then checked daily morning CNI
blood levels to guide future doses [46,48,49]. When using tacrol-
imus with TPV, it is suggested to use 10% of the initial total daily
dose once the morning trough level goes below 3 or 4 ng/ml. In
the ongoing REFRESH study, the reported dosing interval of
tacrolimus ranged from once every 4 to 25 days. In contrast,
the cyclosporine dose is usually 25% of the initial total daily dose
and the dosing interval ranged from once every 1 to 7 days [48].
There is less data available with BOC in LT recipients, but one
study suggested that cyclosporine could be administered at 50%
of the initial total daily dose and given once a day, while the
tacrolimus dose should be started at approximately 25% of the
initial dose and the interval guided by daily assessment of trough
levels [46].
It is also critical to resume dosing of the CNI and mTORi to at
least the pre-treatment dose within 1 to 2 days of BOC and TPV
discontinuation and frequently monitor immunosuppressant
blood levels for the ﬁrst two weeks after BOC and TPV discontin-
uation. Since LT recipients with suppression of HCV replication
have improved hepatic metabolic function, higher daily doses
of the CNI’s and mTORi’s may be required early after discontinu-
ation of BOC and TPV in up to 30% of patients [46,58–60]. There-
fore, close monitoring of immunosuppressant blood levels is
imperative throughout antiviral therapy as well as after discon-
tinuation of BOC and TPV to prevent rejection.Direct acting antivirals in the pipeline
Several DAA’s are in phase 3 development and may gain regula-
tory approval in the near future. Drugs that will likely reach the
marketplace soon include the NS3 protease inhibitors, simeprevir4 vol. 60 j 872–884
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and faldaprevir; the NS5A replication complex inhibitors dacla-
tasvir; and the nucelos(t)ide NS5B polymerase inhibitor, sofosbu-
vir. In addition, an IFN-free regimen consisting of ritonavir
boosted ABT-450, a protease inhibitor, ABT-267, a NS5A inhibitor,
and ABT-333, a non-nucleoside polymerase inhibitor, is demon-
strating promising efﬁcacy results in both treatment naïve and
experienced patients [61,62]. However, IFN-free regimens may
have reduced efﬁcacy in LT recipients that have a high incidence
of HCV genotype 1a, advanced ﬁbrosis, high levels of HCV replica-
tion, and altered drug pharmacokinetics [63].
The new DAA’s offer several potential therapeutic advantages
over the currently approved protease inhibitors, including
improved antiviral efﬁcacy, shorter duration of therapy, and
fewer side effects. Studies of faldaprevir, simeprevir, daclatasvir
and sofosbuvir in combination with PegIFN and RBV have demon-
strated SVR rates, of 70–90% in treatment naïve non-transplant,
HCV genotype 1 patients treated for 12 to 48 weeks [64–71].Table 3. Pharmacokinetic and metabolic parameters of selected oral antiviral agent
Drug and dose Metabolism/
excretion route
CYP inducer or inh
NS3 protease inhibitors
ABT-450/
ritonavir (150 mg q day/ 
100 mg q day)
Hepatic
(CYP3A)
Strong CYP3A inhi
by ritonavir
Boceprevir 800 mg tid Hepatic 
(CYP3A, 
aldoketoreductase)
Moderate CYP3A 
inhibitor
Faldaprevir 120 mg q day 
(BI 20335)
Hepatic 
(CYP3A)
Moderate CYP3A 
inhibitor; weak CYP
inhibitor 
Simeprevir 150 mg q day
(TMC-435)
Hepatic
(CYP3A)
Mild CYP1A2 inhib
mild intestinal/hepa
CYP3A inhibitor
Telaprevir 750 mg tid Hepatic 
(CYP3A)
Strong CYP3A inhi
NS5A replication complex inhibitors
ABT-267 25 mg q day No data No data
Daclatasvir 60 mg q day
(BMS-790052)
Hepatic
(CYP3A)
Not a inducer or inh
of CYP3A4
Ledipasvir 90 mg q day
(GS-5885)
Feces (major);
hepatic and renal 
(minor)
Not a CYP inhibitor
inducer 
Nucleos(t)ide polymerase inhibitors
Sofosbuvir 400 mg q day
(GS-7977)
Renal No clinical evidenc
of CYP inhibition or
induction
Non-nucleoside polymerase inhibitors
ABT-333 400 mg BID Hepatic
CYP2C8 (60%); 
CYP3A4 (30%);
CYP2D6 (10%)
Not a CYP3A induc
Deleobuvir 600 mg BID
(BI-207127)
No data No data
BCRP, breast cancer resistance protein; BID, two times a day; CYP, cytochrome P450; MRP
P-gp, P-glycoprotein; q, every day; UGT, uridine glucuronly transferase.
Adapted from Kiser JJ, et al. [32].
Journal of Hepatology 201Furthermore, the addition of two DAA’s to PegIFN and RBV has
demonstrated an almost 100% SVR even in historically difﬁcult
to treat populations [72,73]. In addition, sofosbuvir combined
with ribavirin alone for 12 weeks is associated with a 97% SVR
in genotype 2 and 67% SVR in genotype 3 patients [74,75]. The
use of ledipasvir in combination with sofosbuvir and ribavirin
may be particularly attractive in LT recipients with genotype 1
infection [76,77]. Many of the new DAA’s also have improved bio-
availability and longer half-lives requiring less frequent dosing
and do not require administration with food.
Available data also suggest a lower likelihood of clinically
signiﬁcant DDI’s with some of the new DAA’s compared to BOC
and TPV (Table 3) [32,82,83,85,87–89]. However, several are
CYP3A and drug transporter substrates and inhibitors. For
example, the AUC of tacrolimus decreased by 17% and that of
cyclosporine increased by 19% with simeprevir co-administration
[78]. ABT-450 is an inhibitor of OATP1B1 that leads tos for hepatitis C.
ibitor Transporter substrate 
or inhibitor
Comments
bition Inhibitor of OATP1B1 Unconjugated hyperbilirubinemia
Weak P-gp inhibitor
CYP3A substrate drugs
Significant DDI’s with other
Significant DDI’s with other
2C9 
Inhibits OATP1B1, 
OATP1B2, OATP2B1; 
Substrate of P-gp and 
MRP2
Inhibition of UGTA1 results in 
unconjugated hyperbilirubinemia
itor; 
tic 
Inhibitor of OATP1B1 
and MRP2
Unconjugated hyperbilirubinemia 
commonly seen
bitor Moderate P-gp inhibitor
CYP3A and P-gp substrate drugs
No data AUC and CMax increased 
62% and 67% by ritonavir, 
respectively
ibitor Moderate inhibitor of 
P-gp and OATP1B1
 or Weak inhibitor of P-gp, 
OATP1B1
e 
 
Substrate of P-gp Dose reduction if moderate to 
severe renal impairment
er
Substrate of P-gp, 
BCRP, OATP1B1, 
OATP1B3
, multiple drug resistance protein; OATP, organic anion transporting polypeptide;
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unconjugated hyperbilirubinemia and the boosting of its bio-
availability with ritonavir, a potent CYP3A4 substrate, may create
difﬁculties in the LT population [79]. Although, sofosbuvir does
not undergo metabolism via CYP3A, dose adjustments are antic-
ipated for patients with moderate or severe renal impairment.
Faldaprevir can lead to unconjugated hyperbilirubinemia via
inhibition of UGT1A1 [80]. Lastly, simeprevir is a substrate of
OATP1B1 and results in an increase in total bilirubin levels in
subjects treated with ribavirin [81].
Data regarding the safety and efﬁcacy of the new DAA’s in var-
ious special patient populations like LT recipients will likely be
lacking at the time of their approval. Therefore, careful scrutiny
of available pharmacokinetic and clinical data will be essential
for successful use of these new drugs in the transplant setting.
Administration of daclatasvir with PegIFN and RBV for 24 weeks
in an LT recipient with severe cholestatic HCV infection led to an
SVR [82]. In addition, the ﬁrst ever successful use of an IFN-free
regimen consisting of sofosbuvir and daclatasvir in a LT recipient
with FCH was recently reported [83]. Sofosbuvir combined with
ascending doses of ribavirin for 24 weeks was also associated
with a 77% week 4 post-treatment response rate and excellent
tolerability in a recent pilot study [84]. However, large, prospec-
tive, multicenter studies are needed to determine the optimal
agent(s), duration of therapy, and safety proﬁle of the new DAA’s
in LT recipients [86].Idiosyncratic drug induced liver injury in the transplant
setting
Drug-induced liver injury (DILI) is an increasingly recognized
cause of clinically signiﬁcant acute and chronic liver disease in
both children and adults [90,91]. DILI is a leading cause of acute
liver failure (ALF) in western countries and the most common
reason for removal of approved medications from the market-
place [92,93]. However, most cases of DILI are ‘‘idiosyncratic’’
and not associated with the dose or duration of medication
administered nor obvious clinical risk factors. Furthermore, the
protean clinical and laboratory presentations of liver injury due
to a particular drug coupled with the lack of an objective and con-
ﬁrmatory diagnostic test frequently leads to a delay in diagnosis
[94,95].DILI in the general population
The incidence of DILI in the general population is not well known.
However, DILI accounts for <1% of consecutive acute liver disease
cases seen in referral centers with viral hepatitis, pancreaticobil-
iary disease, hepatic ischemia, and alcohol being much more
common [96–98]. More recently, the incidence of DILI in the
250,000 adult inhabitants of Iceland was estimated to be 19.1
cases per 100,000 patient years [99]. In western countries, the
majority of DILI cases are attributed to antibiotics, anticonvul-
sants, and psychiatric medications (Table 4) [100,101]. However
herbal and dietary supplements (HDS) can also cause clinically
signiﬁcant liver injury [102]. The Drug Induced Liver Injury Net-
work (DILIN) demonstrated that 73% of DILI cases in the United
States were attributed to a single prescription medication while
9% were attributed to a single or multiple HDS products and
18% were attributed to multiple medications [100].878 Journal of Hepatology 201The diagnosis of DILI rests on ﬁnding abnormalities in serum
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase, or total bilirubin levels while on
the drug compared to pretreatment baseline values. Causality
assessment is largely a diagnosis of exclusion that relies on
(1) time from drug initiation to DILI onset, (2) clinical and lab-
oratory features at presentation, (3) the time and course of
recovery after drug discontinuation (i.e., de-challenge), (4) pres-
ence of established risk factors, (5) exclusion of competing
causes of liver injury, and (6) previous reports on the hepatotox-
icity of the implicated agent. Recently, a checklist of the essen-
tial elements to consider in investigating a possible DILI case
was published [103]. Ongoing studies involving proteomic,
genomic, transcriptomic, and lymphocyte proliferation assays
are attempting to identify biomarkers associated with DILI path-
ogenesis and diagnosis but currently there are no reliable, con-
ﬁrmatory blood tests to accurately establish a diagnosis of DILI
[104]. Causality assessment instruments can assist with DILI
case recognition, but expert opinion appears to be a more
reliable and accurate diagnostic method but is not widely
available nor generalizable [105,106]. The LiverTox website at
http://www.livertox.nih.gov/ was recently established by the
NIH and National Library of Medicine to provide up-to-date
and evidence based information on the hepatotoxicity proﬁle
of over 600 marketed drugs [107]. One recent study suggested
that drugs given in daily doses exceeding 100 mg/day and those
that are more lipophilic in nature may be more likely to cause
hepatotoxicity [108].
The clinical course of DILI can be categorized as hepatocellu-
lar, cholestatic or mixed, based upon the presenting laboratory
proﬁle and liver histology [90]. The severity of a DILI episode
can vary from asymptomatic to severe and life threatening. DILIN
has established a 5-point system for grading severity based on
symptoms, jaundice, need for hospitalization, and signs of hepa-
tic failure [109]. DILIN and other groups have demonstrated that
subjects who present with severe hepatocellular injury that are
jaundiced at the time of hospitalization may have as high as a
10% mortality rate validating ‘‘Hy’s law’’ [100,101].Studies of DILI in the transplant setting
In the LT setting, exclusion of biliary, infectious, vascular, and
immunological causes of allograft dysfunction is essential since
they are more likely to cause liver injury than DILI. Furthermore,
LT recipients may also develop recurrent disease in their allograft
[110]. In addition, idiopathic ‘‘alloimmune hepatitis’’ can develop
at any time post-LT even in previously stable patients [111,112].
Finally, some solid organ transplant recipients may be chronically
infected with hepatitis E virus and misdiagnosed as having DILI
[113,114]. Therefore, a thorough evaluation for competing causes
of liver injury using molecular diagnostic assays, liver imaging,
and liver histology is required to exclude the myriad causes of
allograft dysfunction in LT recipients.
Patients with liver disease may be at increased risk of
developing DILI due to altered pharmacokinetics, up-regulated
intrahepatic cytokine expression, and alterations in drug-
metabolizing pathways [115,116]. For example, subjects with
HIV and HCV or HBV co-infection are at greater risk of developing
serum ALT elevations during anti-retroviral therapy compared to
HIV mono-infected patients [116]. However, it can be4 vol. 60 j 872–884
Table 4. Presentation and outcomes with DILI in the general population and LT recipients.
Feature DILIN US
n = 300
[100]
Spain
n = 446
[101]
Mayo-Liver transplant
n = 29
[118]
Study design Prospective multicenter
(8 sites)
2004 to 2008
Prospective multicenter
(32 sites)
1994-2005
Retrospective LT center 
(1 site) 
1985-2010
Causality method DILIN
Expert opinion
RUCAM DILIN 
Expert opinion
Follow-up duration (mo) 6 to 24 3 n.a.
Mean age (yr) 48 53 52
Female (%) 60 49 52
Race
Caucasian (%)
African American (%) 
Asian (%)
Other (%)
79
11
4
6
100 n.a.
Liver injury type
Hepatocellular (%)
Mixed/cholestatic (%)
57
20/23
58
22/20
7
4/89
Jaundice (%) 69 71 24
Liver biopsy (%) 50 25 96
Hospitalized (%) 60 53 8
Died or transplanted (%) 10 7 0
Median duration medication use (d) 42 105 57
Suspect drugs
Antibiotics (%)
Psychotropic (%)
HDS products (%)
Hypolipidemic (%)
Immunosuppressants (%)
45
15
9
3
1
32
17
0
3
0
58
4
4
7
14
n.a., not available; mo, months; yr, years.
JOURNAL OF HEPATOLOGYexceedingly difﬁcult to reliably distinguish a ﬂare in the underly-
ing liver disease from a DILI episode.Case series
Currently, there is a paucity of data on the frequency, etiologies,
and outcomes with DILI in the LT setting. Nonetheless, LT recipi-
ents may be more susceptible to DILI due to the presence of
circulating donor macrophages that may process or present
neoantigens to host T cells as well as the frequent use of multiple
drugs in LT recipients. Recently, DILI was implicated in 131
Chinese LT recipients undergoing protocol liver biopsies at a
single center over a 6-year period [117]. Of note, 44% of the DILI
cases occurred within the ﬁrst 30 days of LT and antifungal
agents were the leading suspect drug (29%). All of the patients
survived and improved during follow-up. However, the criteria
used to establish a diagnosis of DILI and the extent to which other
causes of allograft dysfunction were excluded are unclear. In
addition, many of the liver biopsy samples demonstrated
evidence of hepatic steatosis and necrosis, which are commonly
encountered in the early post-LT setting.
The frequency and risk factors for DILI in 1689 consecutive LT
recipients from Mayo Clinic seen over a 15 year period were also
recently reported [118]. A diagnosis of ‘‘Deﬁnite DILI’’ was based
on the presence of clinical criteria and a compatible liver biopsyJournal of Hepatology 201after rigorous exclusion of competing causes using expert opinion
for causality assessment [103]. Of the 79 patients with suspected
DILI based upon pathology records, there were only 28 individu-
als who met clinical criteria for ‘‘deﬁnite DILI’’ leading to an over-
all DILI incidence of 1.7%. The mean age of the DILI patients was
52 years and 52% were women. The major indications for LT in
these 28 patients were primary sclerosing cholangitis (28%), chol-
angiocarcinoma (14%) and hepatocellular carcinoma (14%) with
the former being over-represented compared to non-DILI LT
recipients. The DILIN severity scores were mild [1] or moderate
[2] in 92% of the patients (Table 4). The median duration of sus-
pect medication use was 57 days and the most frequently identi-
ﬁed drugs were antibiotics (48%), immunosuppressive agents
(14%), and hypolipidemics (7%). Trimethoprim-sulfamethoxazole
(TMP-SMZ) was the single most commonly implicated drug. The
serum aminotransferase levels normalized during a median fol-
low-up of 34 days after drug withdrawal. There was no clear rela-
tionship between donor characteristics nor time interval since LT
and DILI diagnosis.
These intriguing data suggest that the incidence of DILI in LT
recipients of 1.7% is substantially higher (i.e., 100 fold) than that
reported in the general population (0.02%). Prior studies of
immunosuppressed patients with HIV infection have also demon-
strated that they are at increased risk of developing hepatotoxic-
ity from TMP-SMZ and isoniazid [119]. There are also prior case
reports of LT recipients acquiring food allergies from the donor4 vol. 60 j 872–884 879
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[120]. Therefore, immunosuppressed LT recipients may be at
increased risk of developing DILI.Hepatotoxicity of frequently used drugs in LT recipients
Immunosuppressants
Azathioprine, a prodrug of mercaptopurine that inhibits T cell
maturation, has been a backbone of immunosuppressive regi-
mens in LT recipients for several decades. Patients with low levels
or deﬁciency in thiopurine methyltransferase, which affects10%
of the population, have a higher rate of myelotoxicity with aza-
thioprine use but do not appear to have a higher incidence of DILI.
Azathioprine leads to hepatotoxicity in up to 1–5% of non-trans-
plant patients treated for prolonged periods of time [121,122].
Many of these patients present with mild hepatocellular injury
or cholestasis, which resolves with drug discontinuation. Individ-
ual case reports have also described nodular regenerative
hyperplasia with prolonged exposure to high dose azathioprine
in LT recipients, who frequently present with a cholestatic
laboratory proﬁle [123,124]. The pathophysiology of this lesion
is believed to be due to endothelial cell damage that leads to
sinusoidal dilatation and obliterative pericentral veno-occlusive
changes. Despite its widespread use, acute hepatocellular injury
attributed to mycophenolate mofetil has been only rarely
reported [125–127].
Hepatotoxicity attributed to cyclosporine and tacrolimus also
appears to be uncommon in light of their near universal use in
hundreds of thousands of solid organ transplant recipients. Indi-
vidual cases of cholestatic liver injury following the use of tacrol-
imus have been reported, which usually improved with dose
reductions or switching to an alternative agent [128–131]. Severe
acute hepatocellular injury with jaundice was previously
reported in kidney transplant patients receiving high doses of
cyclosporine with histological features of cholestasis and peri-
cholangitis [130,131]. The mechanism of this intrahepatic chole-
stasis may be due to inhibition of canalicular bile ﬂow and
inhibition of bile salt export pump (BSEP) [132]. However, testing
for HCV and other causes of viral infection were not routinely
done in these early studies and many of the patients appeared
to improve with cyclosporine dose reduction. Sirolimus has been
reported to cause liver injury in HCV patients but clinically
apparent DILI attributed to the recently approved everolimus
has not been reported [133–135].
Antibiotics
Antibiotics are commonly used to prevent and treat bacterial and
fungal infections post-transplant. Amoxicillin-clavulanate is a
leading cause of DILI in the general population and has also been
associated with DILI in a pediatric LT recipient [100,136]. TMP-
SMZ can cause a cholestatic liver injury within a few days to
weeks of drug initiation with prominent hypersensitivity features
of skin rash, fever, and eosinophilia [137]. A minority of patients
treated with TMP-SMZ may also develop life-threatening DRESS
syndrome (Drug Rash, Eosinophilia, and Systemic Symptoms)
while others have mild biochemical liver injury and hepatic gran-
ulomas on biopsy [138]. The presenting liver injury pattern is
typically cholestatic or mixed and may be associated with pro-
longed jaundice. As with other sulfonamides, TMP-SMZ has also880 Journal of Hepatology 201been linked to cases of severe acute hepatocellular injury that
may be severe and even fatal.
The azole antifungals are frequently used to treat and prevent
systemic and superﬁcial fungal infections in LT recipients. In
addition to being potent inhibitors of CYP3A4, ﬂuconazole can
cause mild to moderate serum aminotransferase elevations in
up to 5% of treated patients. Fluconazole, as well as the other
azole antifungals (e.g., itraconazole, voriconazole, ketoconazole),
can also rarely lead to severe acute hepatocellular injury with
jaundice [139,140].
Isoniazid is a leading cause of severe acute DILI that may
result in emergency LT [92]. In these instances, anti-tuberculosis
(TB) prophylaxis with an alternative regimen containing a quino-
lone, rifampin, or amikacin may be required in the early post-LT
setting to prevent TB reactivation [141]. The optimal time and
duration of isoniazid therapy for LT recipients with latent TB
remains unclear, but should generally be deferred until at least
6 months post-LT to reduce the risk of inadvertent hepatotoxicity
[142,143].
Antiviral agents
Ganciclovir and valganciclovir are frequently used to treat and
prevent cytomegalovirus infection in the LT setting. Neither agent
has been associated with clinically apparent liver injury, but
intravenous administration of ganciclovir is associated with mild
to moderate increases in serum ALT levels in 2% of treated
patients that are typically self-limited [144].
Other agents
Individuals who consume weight loss products that contain
green tea extract with variable amounts of catechins may develop
severe acute hepatocellular injury with jaundice including LT
recipients [145,146]. Other drugs associated with DILI in LT recip-
ients include sorafenib to treat recurrent liver cancer and intrave-
nously administered amiodarone for peri-operative atrial
ﬁbrillation [147–149].Conclusions
The introduction of potent and highly effective DAA’s has ush-
ered in a new era in the management of both LT candidates
and recipients with HCV infection. Knowledge of the metabolic
pathways involved in the elimination of these agents will be
critical for their optimal and safe use in the LT population. Clin-
ically signiﬁcant DDI’s have consistently been reported in LT
recipients treated with TPV and BOC, which mandate empiric
CNI dose reductions and intensive monitoring of immunosup-
pressant blood levels during and after their discontinuation. It
is anticipated that several of the HCV polymerase inhibitors,
NS5A replication complex inhibitors, and 2nd generation prote-
ase inhibitors will be associated with fewer DDI’s and adverse
effects but prospective studies of these agents in LT recipients
are needed. Finally, LT recipients appear to be at increased risk
of developing DILI from various antibiotics, immunosuppres-
sants, and hypolipidemics. An improved awareness of the poten-
tial for DILI in the LT setting will hopefully lead to earlier
discontinuation of the suspect drug and help minimize allograft
injury.4 vol. 60 j 872–884
JOURNAL OF HEPATOLOGYKey Points
• Boceprevir and telaprevir based antiviral therapy
are associated with improved response rates in
liver transplant (LT) recipients with HCV genotype 1
infection compared to historical controls, but also with
more frequent and potentially severe side effects such
as anemia
• Clinically significant drug interactions with boceprevir
and telaprevir mandate empiric calcineurin inhibitor
dose reductions and frequent immunosuppressant
blood level monitoring during and after treatment to
prevent toxicity and subtherapeutic dosing, respectively
• Use of the protease inhibitors, simeprevir and
faldeprevir, as well as daclatasvir and sofosbuvir will
likely be associated with improved antiviral response
rates in LT recipients as well as fewer side effects;
however, the optimal agent(s) and duration of therapy
require further study
• Liver transplant recipients appear to be at increased
risk of developing drug-induced liver injury 
(DILI) from a multitude of agents with antibiotics,
immunosuppressants, and hypolipidemic agents most
frequently implicated
• Differentiating DILI from other causes of allograft
dysfunction is challenging but important so that the
suspect drug can be promptly discontinuedFinancial support
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